Dec 18 2009
The board of directors of BioNanomatrix, Inc., a developer of breakthrough single-molecule genomic analysis technology, has elected Edward L. Erickson company president and chief executive officer.
Erickson, who was executive chairman of the board, succeeds Michael Boyce-Jacino, who has stepped down as president and CEO and from the board. Battelle Ventures General Partner Tracy Warren succeeds Erickson as chairperson.
“As the company rapidly approaches commercialization of its NanoAnalyzer® system in the coming year, initially for advanced DNA analysis,” said Warren, “the board has implemented these changes to prepare for late-stage product testing at major research institutions and for market introduction thereafter.
“Mike’s scientific expertise helped guide the company through its initial venture funding and early product development,” she continued, “and now Ed has taken the reins, to directly apply his extensive experience in the development and commercialization of life science research products, diagnostic platforms and other medical products.”
Noting that Erickson has served as president, CEO or a director of more than a dozen life-science-based companies, three of which successfully completed IPOs under his leadership,. Warren added that he has been on the BioNanomatrix board since the company’s first venture financing.
“As the company moves into the commercial phase of its development, we’re confident that under Ed’s leadership BioNanomatrix will successfully advance through the critical steps necessary to achieve significant market acceptance and adoption,” she said.